Share This Page
Suppliers and packagers for generic pharmaceutical drug: oseltamivir phosphate
✉ Email this page to a colleague
oseltamivir phosphate
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alembic | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 211823 | ANDA | Alembic Pharmaceuticals Limited | 46708-413-10 | 1 CARTON in 1 BLISTER PACK (46708-413-10) / 10 CAPSULE in 1 CARTON | 2019-06-25 |
| Alembic | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 211823 | ANDA | Alembic Pharmaceuticals Limited | 46708-414-10 | 1 CARTON in 1 BLISTER PACK (46708-414-10) / 10 CAPSULE in 1 CARTON | 2019-06-25 |
| Alembic | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 211823 | ANDA | Alembic Pharmaceuticals Limited | 46708-415-10 | 1 CARTON in 1 BLISTER PACK (46708-415-10) / 10 CAPSULE in 1 CARTON | 2019-06-25 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Oseltamivir Phosphate
Introduction
Oseltamivir Phosphate, marketed primarily under the brand name Tamiflu, is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza A and B. Its critical role in pandemic preparedness and seasonal flu management has driven global demand, prompting a complex supply chain comprising multiple suppliers ranging from active pharmaceutical ingredient (API) manufacturers to finished dosage form producers. Understanding the global landscape of Oseltamivir Phosphate suppliers is essential for pharmaceutical companies, healthcare authorities, and investors aiming to navigate supply risks, ensure procurement stability, or explore manufacturing capabilities.
API Manufacturing and Key Suppliers
1. Major API Manufacturers
The fundamental ingredient of Oseltamivir Phosphate, the API, is produced by several pioneering pharmaceutical and chemical companies worldwide. Historically, China and India have dominated the API manufacturing landscape due to lower production costs, advanced chemical synthesis capabilities, and established export infrastructure.
a. Hetero Labs (India)
Hetero Labs has established itself as a prominent API manufacturer for Oseltamivir Phosphate, leveraging extensive experience in complex chemical synthesis and robust production facilities. The company's supply capacity has been critical in meeting global demand, especially during influenza pandemics. Hetero's APIs are supplied to several generic drug makers globally, including those in North America and Europe.
b. Dr. Reddy’s Laboratories (India)
Another leading producer, Dr. Reddy’s, offers high-quality Oseltamivir Phosphate APIs. Their manufacturing facilities are licensed by global regulatory agencies, including the U.S. FDA, providing confidence in the safety and consistency of their supply.
c. Zhejiang Hisun Pharmaceutical (China)
Chinese pharmaceutical companies like Zhejiang Hisun Pharma manufacture Oseltamivir Phosphate API, rapidly scaling production during health crises. Their strategic position within China enables cost-effective and swift supply chain mobilization.
d. Hunan Hande Biotechnology (China)
This Chinese biotech firm has expanded API production capacities, including Oseltamivir Phosphate, often collaborating with local government initiatives for pandemic response.
2. Contract Manufacturing Organizations (CMOs)
Numerous CMOs operate under licensing agreements to produce Oseltamivir Phosphate APIs for global pharmaceutical firms, increasing capacity and mitigating risks associated with single-source suppliers.
a. Jiangsu Saike Biological Technology (China)
Specializes in antiviral APIs, including Oseltamivir Phosphate, with large-scale production capabilities.
b. Santanu Biosciences (India)
Provides contract manufacturing for high-volume APIs, including Oseltamivir Phosphate, serving both generic and innovator companies.
Finished Dosage Form Manufacturers
While API manufacturers form the core supply system, several pharmaceutical companies produce the finished Oseltamivir Phosphate formulations, often sourcing APIs from multiple suppliers.
1. Gilead Sciences
Original developer of Tamiflu, Gilead Sciences, licensed manufacturing to Roche and other partners, maintaining tight control over the formulation process. During the 2009 H1N1 pandemic, Gilead partnered with generic manufacturers to expand access.
2. Generic Manufacturers
Global generic firms—such as █████████, █████████, and █████████—source APIs from the aforementioned suppliers to produce and distribute Oseltamivir-based medicines. Market penetration varies based on local regulatory approvals and supply agreements.
Supply Chain Considerations and Challenges
a. Dependence on Chinese and Indian Suppliers
The majority of Oseltamivir Phosphate APIs originate from China and India, introducing potential risks from geopolitical tensions, tariffs, export restrictions, and pandemics affecting manufacturing continuity.
b. Regulatory Compliance
Suppliers must adhere to Good Manufacturing Practices (GMP) and obtain approvals from regulatory bodies such as the FDA and EMA. Regulatory divergence can complicate procurement from certain regions.
c. Supply Chain Disruptions
Historical instances—such as the COVID-19 pandemic—highlight vulnerabilities in the supply chain, affecting API availability and leading to increased reliance on diverse suppliers and strategic stockpiling.
Emerging Trends and Alternative Suppliers
1. Diversification of Supply Sources
To reduce dependency on geographic concentration, players are increasingly engaging with multiple suppliers within different jurisdictions, including Southeast Asia and Eastern Europe.
2. Localized Production Initiatives
Some countries are investing in domestic API manufacturing capabilities, aligned with policies aiming for supply chain resilience.
3. Synthetic and Biotechnological Innovations
Research into alternative synthetic pathways and biotechnological production methods presents future potential for more stable and scalable API supply.
Conclusion
The supply ecosystem for Oseltamivir Phosphate is highly globalized, primarily centered around key API manufacturers in China and India, with significant contributions from CMOs and finished dosage producers worldwide. Pharmaceutical companies and health authorities must remain vigilant to geopolitical, regulatory, and pandemic-related risks, emphasizing diversification and strategic stockpiling. An evolving landscape driven by technological advances and geopolitical shifts will shape future procurement strategies, ensuring continuous access to this essential antiviral.
Key Takeaways
- The primary Oseltamivir Phosphate API suppliers are based mainly in China and India, with companies like Hetero Labs, Dr. Reddy’s, and Zhejiang Hisun Pharma leading the market.
- Contract manufacturing organizations enhance capacity and supply chain flexibility, mitigating risks associated with single-source dependencies.
- Regulatory compliance remains a critical determinant of supplier credibility, with licensed facilities ensuring quality and safety.
- Geopolitical tensions and pandemic-related disruptions underscore the importance of diversification and strategic reserve planning.
- Emerging manufacturing innovations and regional production initiatives are vital for future supply chain resilience.
FAQs
1. Who are the leading global API suppliers for Oseltamivir Phosphate?
Leading API suppliers include Hetero Laboratories and Dr. Reddy’s Laboratories in India, as well as Zhejiang Hisun Pharmaceutical and Hunan Hande Biotechnology in China.
2. How does supply chain concentration impact Oseltamivir Phosphate availability?
Heavy reliance on Chinese and Indian suppliers increases vulnerability to geopolitical tensions, export restrictions, and pandemic disruptions, highlighting the need for diversification.
3. Are there regulatory hurdles for Oseltamivir Phosphate suppliers?
Yes. Suppliers must obtain GMP certifications from authorities like the FDA and EMA, which can influence supply continuity based on regulatory compliance and inspection outcomes.
4. What role do contract manufacturing organizations play in Oseltamivir Phosphate supply?
CMOs expand production capacity, provide flexibility, and reduce dependency on single manufacturers, especially during surge demands like pandemics.
5. Are there ongoing innovations in Oseltamivir Phosphate production?
Research into alternative synthesis routes and biotechnological methods aims to improve yields, reduce costs, and enhance supply chain resilience.
References
[1] Gilead Sciences, Tamiflu Product Information.
[2] World Health Organization Reports on Influenza Antiviral Supply Chains.
[3] GlobalData, API Market Analysis — Oseltamivir Phosphate.
[4] U.S. FDA, Drug Establishments Manufacturing Oseltamivir Phosphate.
[5] Industry reports on recent developments in antiviral manufacturing.
More… ↓
